ImmunoGen

THE PANCREATIC CANCER ACTION NETWORK NAMES ANNA BERKENBLIT, MD, MMSc AS FIRST-EVER CHIEF SCIENTIFIC AND MEDICAL OFFICER

Retrieved on: 
Tuesday, April 2, 2024
Harvard Medical School, Health, Growth, ImmunoGen, Patient, Research, MD, MBA, Outline of health sciences, Pancreatic Cancer Action Network, Pancreatic cancer, Biomedicine, FDA, MMSc

LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.
  • "And I'm really excited to join PanCAN to build on our scientific and medical initiatives to take PanCAN to the next phase of growth."
  • "We are honored to welcome Dr. Berkenblit to PanCAN as our first-ever chief scientific and medical officer.
  • She will serve as a thought leader for us in the pancreatic cancer scientific and medical community working with our external advisors and stakeholders," said Fleshman.

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Retrieved on: 
Friday, March 22, 2024
AbbVie, Ovarian cancer, Survival, ImmunoGen, Progression-free survival, Patient, Neoplasm, ABBV, Malignancy, University, Mirvetuximab soravtansine, PROC, Cancer, PFS, ADC, Food, FDA, Medicine, Pharmaceutical industry

NORTH CHICAGO, Ill., March 22, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies. Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy. They may become resistant to this treatment and require another therapy, such as ELAHERE.  

Key Points: 
  • Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy.
  • They may become resistant to this treatment and require another therapy, such as ELAHERE.
  • "The full FDA approval of ELAHERE for eligible patients with ovarian cancer represents the culmination of years of work by the ImmunoGen team.
  • "As the first treatment to show a statistically significant overall survival benefit in patients with platinum-resistant ovarian cancer, ELAHERE provides an effective new option for patients with folate receptor alpha positive tumors.

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
Research, AbbVie, Sale, Carcinoma, Lung cancer, Webcast, Anal cancer, Acute myeloid leukemia, Trial of the century, Melanoma, Head, Neck, SCLC, SCCHN, GAAP, ADAM, B7, Therapy, NSCLC, Syndrome, CD123, ID, AACR, Conference, Safety, Enoblituzumab, ImmunoGen, Clinical trial, Half-life, IND, Conference call, Docetaxel, ASCO, Telephone, Cancer, Spacecraft, HEAT, ADAM9, ADC, Society, Patient, Pharmaceutical industry

ET

Key Points: 
  • ET
    ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
  • “We expect that 2024 will be an important year for MacroGenics, with multiple pipeline advancements anticipated," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.

AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer

Retrieved on: 
Tuesday, February 20, 2024
ABBV, Adalimumab, Growth, AbbVie, ImmunoGen, Patient, Management

Transition will occur on July 1, 2024

Key Points: 
  • Transition will occur on July 1, 2024
    NORTH CHICAGO, Ill., Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO).
  • "On behalf of AbbVie's board, I am extremely excited that Rob has agreed to serve as AbbVie's next CEO," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.
  • "As a key member of the Executive Leadership Team, he has had a tremendous impact on AbbVie.
  • "I am honored to assume the CEO role for AbbVie, and I am excited about our company's bright future," said Robert A. Michael, president and chief operating officer, AbbVie.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Spacecraft, Employment, Cancer, ImmunoGen, IMGN, RSU, Vaccine

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of January 31, 2024, the grant of restricted stock units (“RSUs”) covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to eleven new employees.

Key Points: 
  • ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of January 31, 2024, the grant of restricted stock units (“RSUs”) covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to eleven new employees.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter for the next three years, subject to the employee’s continued employment on each vesting date.
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an RSU agreement covering the grants.

SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates ROVR, ICVX, HA, IMGN

Retrieved on: 
Saturday, January 13, 2024
ImmunoGen, Rover Group, Rover, Fraud, Sale, Advertising, AbbVie, Blackstone Inc., AstraZeneca, Hawaiian Airlines, Security (finance)

If you are a Rover shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Rover shareholder, click here to learn more about your rights and options .
  • If you are an Icosavax shareholder, click here to learn more about your rights and options .
  • If you are a Hawaiian shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Spacecraft, ImmunoGen, Employment, IMGN, RSU, Vaccine

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of December 29, 2023, the grant of restricted stock units (“RSUs”) covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to six new employees.

Key Points: 
  • ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of December 29, 2023, the grant of restricted stock units (“RSUs”) covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to six new employees.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter for the next three years, subject to the employee’s continued employment on each vesting date.
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an RSU agreement covering the grants.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGN, HA, CERE, HOLI

Retrieved on: 
Monday, January 1, 2024
Advertising, Hawaiian Airlines, Fraud, Sale, ImmunoGen, AbbVie, Security (finance)

If you are an ImmunoGen shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an ImmunoGen shareholder, click here to learn more about your rights and options .
  • If you are a Hawaiian shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, BVH, IMGN

Retrieved on: 
Wednesday, December 27, 2023
Sale, Eargo, Realty Income, ImmunoGen, Fraud, AbbVie, Advertising, Blue-green, Security (finance)

If you are a Spirit Realty shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Spirit Realty shareholder, click here to learn more about your rights and options .
  • If you are an Eargo shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of ICVX, EAR, CVLY, IMGN to Take Action

Retrieved on: 
Wednesday, December 27, 2023
Empire, CVR, IMGN, AstraZeneca, Sale, Monteverde, EAR, ImmunoGen, AbbVie, Eargo, Security (finance)

Under the terms of the agreement, ICVX shareholders are expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share they own.

Key Points: 
  • Under the terms of the agreement, ICVX shareholders are expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share they own.
  • Under the terms of the agreement, EAR shareholders will receive $2.55 in cash per share they own.
  • Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.
  • Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.